Swine Flu. First results of clinical trials

The fresh results from clinical trials 2009 H1N1 Influenza Vaccines In Healthy Adults indicate that this vaccines are well tolerated and induce a strong immune response. The trials are an important part of the ongoing worldwide effort to develop vaccines to protect the public from 2009 H1N1 influenza. More than 2,800 people are participating in ongoing NIAID trials of these vaccines. Preliminary analyses of early data from the NIAID trials align with the recently announced findings and those to be announced imminently by other companies in that both vaccines studied induced what is likely to be a protective immune response in most adults following a single dose in the same amount (15 micrograms) used in seasonal flu vaccines. Specifically, in blood samples obtained 8 to 10 days after vaccination.